Article

Phospholipase C-γ1 interacts with conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk

Department of Microbiology, University of Washington, Seattle, USA.
Molecular and Cellular Biology (Impact Factor: 5.04). 05/1996; 16(4):1305-15.
Source: PubMed

ABSTRACT Antigen receptor ligation on lymphocytes activates protein tyrosine kinases and phospholipase C-gamma (PLC-gamma) isoforms. Glutathione S-transferase fusion proteins containing the C-terminal Src-homology 2 [SH2(C)] domain of PLC-gamma1 bound to tyrosyl phosphorylated Syk. Syk isolated from antigen receptor-activated B cells phosphorylated PLC-gamma1 on Tyr-771 and the key regulatory residue Tyr-783 in vitro, whereas Lyn from the same B cells phosphorylated PLC-gamma1 only on Tyr-771. The ability of Syk to phosphorylate PLC-gamma1 required antigen receptor ligation, while Lyn was constitutively active. An mCD8-Syk cDNA construct could be expressed as a tyrosyl-phosphorylated chimeric protein tyrosine kinase in COS cells, was recognized by PLC-gamma1 SH2(C) in vitro, and induced tyrosyl phosphorylation of endogenous PLC-gamma1 in vivo. Substitution of Tyr-525 and Tyr-526 at the autophosphorylation site of Syk in mCD8-Syk substantially reduced the kinase activity and the binding of this variant chimera to PLC-gamma1 SH2(C) in vitro; it also failed to induce tyrosyl phosphorylation of PLC-gamma1 in vivo. In contrast, substitution of Tyr-348 and Tyr-352 in the linker region of Syk in mCD8-Syk did not affect the kinase activity of this variant chimera but almost completely eliminated its binding to PLC-gamma1 SH(C) and completely eliminated its ability to induce tyrosyl phosphorylation of PLC-gamma1 in vivo. Thus, an optimal kinase activity of Syk and an interaction between the linker region of Syk with PLC-gamma1 are required for the tyrosyl phosphorylation of PLC-gamma1.

Download full-text

Full-text

Available from: Svetlana P. Sidorenko, Aug 16, 2015
0 Followers
 · 
53 Views
  • Source
    • "Src and Fyn are regulated by phosphorylation on two sites: one at tyrosine 416 which is activatory, and the other at tyrosine 527 which is inhibitory (reviewed by Hunter, 1987). Similar phosphorylation sites are found in other SFK members: activation of phosphorylation are at tyrosines 394 for Lck, at tyrosines 323 and 352 for Syk, and inhibition of phosphorylation are at tyrosines 505 for Lck, and at tyrosines 525 and 526 for Syk (Chow et al., 1993; Law et al., 1996; Deckert et al., 1998; Zhang et al., 2000; Rao et al., 2001). Activating phosphorylation often results from autophosphorylation (Chiang and Sefton, 2000; reviewed by Roskoski, 2004; reviewed by Roskoski, 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tau phosphorylation is regulated by a balance between tau kinase and phosphatase activities. Disruption of this equilibrium was suggested to be at the origin of abnormal tau phosphorylation and thereby might contribute to tau aggregation. Thus, understanding the regulation modes of tau phosphorylation is of high interest in determining the possible causes at the origin of the formation of tau aggregates in order to elaborate protection strategies to cope with these lesions in Alzheimer's disease. Among the possible and specific interventions that reverse tau phosphorylation is the inhibition of certain tau kinases. Here, we extensively reviewed tau protein kinases, their physiological roles and regulation, their involvement in tau phosphorylation and their relevance to AD. We also reviewed the most common inhibitory compounds acting on each tau kinase.
    Ageing research reviews 06/2012; 12(1):289-309. DOI:10.1016/j.arr.2012.06.003 · 7.63 Impact Factor
  • Source
    • "Three major MAP kinases, ERK1/2, p38, and JNK, were dose-dependently inhibited by 4-chlorotetrazolo[1,5-a]quinoxaline (Fig. 4B). It is generally believed that Lyn initially phosphorylates the tyrosine 346 residue (Y346) of murine Syk in antigen-stimulated mast cells (Chu et al., 1998; Law et al., 1996). Thus, we examined whether phosphorylation of Syk Y346 was inhibited by 4-chlorotetrazolo[1,5- a]quinoxaline. "
    [Show abstract] [Hide abstract]
    ABSTRACT: 4-Chlorotetrazolo[1,5-a]quinoxaline is a quinoxaline derivative. We aimed to study the effects of 4-chlorotetrazolo[1,5-a]quinoxaline on activation of mast cells in vitro and in mice. 4-Chlorotetrazolo[1,5-a]quinoxaline reversibly inhibited degranulation of mast cells in a dose-dependent manner, and also suppressed the expression and secretion of TNF-α and IL-4 in mast cells. Mechanistically, 4-chlorotetrazolo[1,5-a]quinoxaline inhibited activating phosphorylation of Syk and LAT, which are crucial for early FcεRI-mediated signaling events, as well as Akt and MAP kinases, which play essential roles in the production of various pro-inflammatory cytokines in mast cells. Notably, although 4-chlorotetrazolo[1,5-a]quinoxaline inhibited the activation of Fyn and Syk, minimal inhibition was observed in mast cells in the case of Lyn. Furthermore, consistent with its in vitro activity, 4-chlorotetrazolo[1,5-a]quinoxaline significantly suppressed mast cell-mediated passive cutaneous anaphylaxis in mice. In summary, the results from this study demonstrate that 4-chlorotetrazolo[1,5-a]quinoxaline shows an inhibitory effect on mast cells in vitro and in vivo, and that this is mediated by inhibiting the activation of Syk in mast cells. Therefore, 4-chlorotetrazolo[1,5-a]quinoxaline could be useful in the treatment of mast cell-mediated allergic diseases.
    Toxicology and Applied Pharmacology 09/2011; 257(2):235-41. DOI:10.1016/j.taap.2011.09.009 · 3.63 Impact Factor
  • Source
    • "These include the Bruton's Tyrosine Kinase (Btk) and Phospholipase C-γ (PLCγ ) [20]. When phosphorylated by Btk [21] and by the tyrosine kinase Syk [22], PLCγ is activated and generates inositol-1,4,5-trisphosphate, which triggers the mobilization of intracellular Ca 2+ stores and, secondarily, an influx of "
    [Show abstract] [Hide abstract]
    ABSTRACT: Murine FcgammaRIIB were demonstrated to recruit SH2 domain-containing inositol 5-phosphatases (SHIP1/2), when their ITIM is tyrosyl-phosphorylated upon co-aggregation with BCR, and SHIP1 to account for FcgammaRIIB-dependent negative regulation of murine B cell activation. Although human FcgammaRIIB share the same ITIM as murine FcgammaRIIB and similarly inhibit human B cell activation, which among the four known SH2 domain-containing (tyrosine or inositol) phosphatases is/are recruited by human FcgammaRIIB is unclear. Our recent finding that, besides the ITIM, a second tyrosine-based motif is mandatory for murine FcgammaRIIB to recruit SHIP1 challenged the possibility that human FcgammaRIIB recruit this phosphatase. Human FcgammaRIIB indeed lack this motif. Using an experimental model which enabled us to compare human FcgammaRIIB and murine FcgammaRIIB under strictly controlled conditions, we show that SHIP1 is recruited to the intracytoplasmic domain of human FcgammaRIIB and inhibits the same biological responses and intracellular signals as when recruited by murine FcgammaRIIB. Identical results were observed in murine and in human B cells. We demonstrate that SHIP is necessary for human FcgammaRIIB to inhibit BCR signaling, and cannot be replaced by SHP-1 or SHP-2. Although it contains no tyrosine, the C-terminal segment of human FcgammaRIIB was as mandatory as the tyrosine-containing C-terminal segment of murine FcgammaRIIB for SHIP1 to be recruited to the ITIM. This segment, however, did not recruit the adapters Grb2/Grap which were demonstrated to stabilize the recruitment of SHIP1 to the ITIM in murine FcgammaRIIB.
    Immunology Letters 05/2006; 104(1-2):156-65. DOI:10.1016/j.imlet.2005.11.027 · 2.37 Impact Factor
Show more